StockData

Allogene Therapeutics vs Inmune Bio

ALLO and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLO and INMB compare

Allogene Therapeutics is the larger company, worth 10 times as much as Inmune Bio ($311M against $30.5M).

Inmune Bio scores higher on the StockData Score (6 against 3 for Allogene Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLOINMB
Size and price
Market cap$311M$30.5M
Share price$0.900$1.10
Change, 1 year−23.7%−30.4%
Change, 5 years−95.2%−91.8%
Beta (5Y)1.621.33
Employees1526
StockData Score
Total score36 (better)
Valuation score11
Growth score00
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/B0.8× (better)1.7×
FCF yield−35.0%–
Growth
Revenue growth, 5Y average–35.4%
Profitability
Return on equity−49.3% (better)−76.7%
Return on invested capital−718%–
Financial health
Debt / equity–0.00
Interest coverage−142.5×–
Current ratio7.79 (better)6.41
Altman Z-score−4.92 (better)−10.86
Piotroski F-score34 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions90.5%15.7%
Held by insiders15.0%16.7%
Insider net buying, 12 months−$668K–
Short interest, % of float17.5%11.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.